Rankings
▼
Calendar
RAPP Q4 2023 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
RAPP
Rapport Therapeutics, Inc. Common Stock
$1B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$76,000
Operating Income
-$15M
Net Income
-$14M
EPS (Diluted)
$-0.07
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$12M
Stock-Based Comp.
$998,000
Balance Sheet
Total Assets
$155M
Total Liabilities
$181M
Stockholders' Equity
-$26M
Cash & Equivalents
$70M
← FY 2023
All Quarters
Q1 2024 →